Dyspnea and Bronchoconstriction in a Young Patient With Multiple Sclerosis Treated With Ponesimod

array:23 ["pii" => "S0300289623001837" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.05.018" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "3336" "copyright" => "SEPAR" "copyrightAnyo" => "2023" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Arch Bronconeumol. 2023;59:676-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S0300289623001898" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.06.008" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "3342" "copyright" => "SEPAR" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Arch Bronconeumol. 2023;59:678-80" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:9 [ "idiomaDefecto" => true "cabecera" => "Scientific Letter" "titulo" => "Do Smokers Who Only Attend the First Appointment of a Smoking Cessation Consultation Have Distinguishing Characteristics?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "678" "paginaFinal" => "680" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José Ignacio de Granda-Orive, José Francisco Pascual-Lledó, Santos Asensio-Sánchez, Segismundo Solano-Reina, Marcos García-Rueda, Manuel Ángel Martínez-Muñiz, Lourdes Lázaro-Asegurado, Daniel Buljubasich, Susana Luhning, Rogelio Pendino, Isabel Cienfuegos-Agustín, Carlos A. Jiménez-Ruiz" "autores" => array:12 [ 0 => array:2 [ "nombre" => "José Ignacio" "apellidos" => "de Granda-Orive" ] 1 => array:2 [ "nombre" => "José Francisco" "apellidos" => "Pascual-Lledó" ] 2 => array:2 [ "nombre" => "Santos" "apellidos" => "Asensio-Sánchez" ] 3 => array:2 [ "nombre" => "Segismundo" "apellidos" => "Solano-Reina" ] 4 => array:2 [ "nombre" => "Marcos" "apellidos" => "García-Rueda" ] 5 => array:2 [ "nombre" => "Manuel Ángel" "apellidos" => "Martínez-Muñiz" ] 6 => array:2 [ "nombre" => "Lourdes" "apellidos" => "Lázaro-Asegurado" ] 7 => array:2 [ "nombre" => "Daniel" "apellidos" => "Buljubasich" ] 8 => array:2 [ "nombre" => "Susana" "apellidos" => "Luhning" ] 9 => array:2 [ "nombre" => "Rogelio" "apellidos" => "Pendino" ] 10 => array:2 [ "nombre" => "Isabel" "apellidos" => "Cienfuegos-Agustín" ] 11 => array:2 [ "nombre" => "Carlos A." "apellidos" => "Jiménez-Ruiz" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623001898?idApp=UINPBA00003Z" "url" => "/03002896/0000005900000010/v2_202312180422/S0300289623001898/v2_202312180422/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0300289623002752" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.08.004" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "3383" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2023;59:675" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Clinical Image" "titulo" => "Fanning Technique for Endobronchial Ultrasound-Guided Transbronchial Mediastinal Cryobiopsy: It is Possible" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "675" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1245 "Ancho" => 1908 "Tamanyo" => 193385 ] ] "descripcion" => array:1 [ "en" => "EBUS image showing the 1.1mm cryo-probe inside the station 7 lymph node. By performing the fanning technique, we were able to accurately place the cryo-probe in multiple zones of the lymph node." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Angel Ariza-Prota, Javier Pérez-Pallarés, Francisco López-González" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Miguel Angel" "apellidos" => "Ariza-Prota" ] 1 => array:2 [ "nombre" => "Javier" "apellidos" => "Pérez-Pallarés" ] 2 => array:2 [ "nombre" => "Francisco" "apellidos" => "López-González" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623002752?idApp=UINPBA00003Z" "url" => "/03002896/0000005900000010/v2_202312180422/S0300289623002752/v2_202312180422/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "Scientific Letter" "titulo" => "Dyspnea and Bronchoconstriction in a Young Patient With Multiple Sclerosis Treated With Ponesimod" "tieneTextoCompleto" => true "saludo" => "To the Director," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "676" "paginaFinal" => "677" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Marta Gómez Román, Maria del Mar García Ródenas, Luis Moreno Navarro, Santos Asensio Sánchez, Ángel Pérez Sempere" "autores" => array:5 [ 0 => array:4 [ "nombre" => "Marta" "apellidos" => "Gómez Román" "email" => array:1 [ 0 => "martagoro13@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Maria del Mar" "apellidos" => "García Ródenas" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Luis" "apellidos" => "Moreno Navarro" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 3 => array:3 [ "nombre" => "Santos" "apellidos" => "Asensio Sánchez" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 4 => array:3 [ "nombre" => "Ángel" "apellidos" => "Pérez Sempere" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] 2 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] ] "afiliaciones" => array:5 [ 0 => array:3 [ "entidad" => "Servicio de Neumología, Hospital General Universitario Dr. Balmis, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Instituto de Investigación Sanitaria Biomédica de Alicante (ISABIAL), Alicante, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Neurología, Hospital General Universitario Dr. Balmis, Alicante, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Instituto de Investigación Sanitaria Biomédica de Alicante (ISABIAL), Grupo 1: Investigación en Neurociencias, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Departamento de Medicina Clínica, Universidad Miguel Hernández, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 805 "Ancho" => 1258 "Tamanyo" => 51089 ] ] "descripcion" => array:1 [ "en" => "Flow-volume chart after discontinuing ponesimod." ] ] ] "textoCompleto" => "The emergence of immunotherapy for the treatment of autoimmune diseases has revolutionized the management of many diseases in recent years, including multiple sclerosis (MS). Ponesimod is a highly selective sphingosine-1-phosphate receptor (S1PR) modulator that shows high-affinity binding to subtype 1 (S1PR1) in lymphocytes and other cells. Ponesimod prevents lymphocytes from leaving the lymph nodes, thus reducing their concentration in peripheral blood. Its mechanism of action in MS has not been fully clarified, but its therapeutic effects are probably associated with the reduced migration of lymphocytes to the central nervous system (CNS).<a class="elsevierStyleCrossRefs" href="#bib0035">1,2</a> This drug has been marketed in Spain for the treatment of recurrent forms of MS since 2022.We report a little-known adverse effect in a young woman with no respiratory history who, after starting ponesimod, developed symptoms of progressive dyspnea reaching modified scale of the Medical Research Council (mMRC) grade 3 and mild obstruction with bronchial reversibility in spirometry.Our patient was a 34-year-old woman diagnosed in 2011 with relapsing-remitting MS. After therapeutic failure with cladribine, she began treatment with ponesimod in January 2023. Neurological examination on starting ponesimod was normal. Within 3 weeks of administration, the patient developed dyspnea that limited her activities of daily living, eventually reaching mMRC grade 3. In view of these symptoms, she was referred to the respiratory medicine department for further investigation. The patient reported no cough, expectoration, wheezing, chest tightness or other symptoms associated with her dyspnea. She had no history of asthma or bronchial hyperreactivity during respiratory infections. She had no known respiratory history, no history of nasal polyposis, no NSAID intolerance, no IgE elevation or peripheral eosinophilia, and had never required bronchodilator treatment. Spirometry was performed, showing FVC 4550ml (107%), FEV1 3040ml (86%), FEV1/FVC 0.67 (80% predicted), consistent with mild obstructive ventilatory airflow changes. A bronchodilator challenge with 400mcg of salbutamol produced a significant 16.7% improvement in FEV1 from baseline (510ml), 14.5% improvement in predicted value, and reversibility of obstruction with normalization of FEV1/FVC (0.75) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). A pulmonary carbon monoxide diffusion (DLCO) test was performed with a result of 107% (within normal limits) and an exhaled nitric oxide (FeNO) measurement of 23ppb. The study was completed with high-resolution computed tomography of the chest that revealed no significant radiological alterations.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Given these findings, we initially planned to start bronchodilator treatment, but the temporal relationship of symptoms with the start of ponesimod suggested that bronchoconstriction was due to this therapy, so we decided to discontinue the drug and replace it with ofatumumab, an anti-CD20 monoclonal antibody, without adding bronchodilator therapy. The patient's respiratory symptoms resolved 2 weeks after discontinuing ponesimod. Spirometry was repeated showing parameters within normal limits: FEV1 5060ml (118%), FEV1 3760ml (106%), FEV1/FVC 74% (89% predicted) (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).<elsevierMultimedia ident="fig0010"></elsevierMultimedia>The patient's good progress following discontinuation of ponesimod, with resolution of dyspnea and normalization of spirometry values, suggests that her symptoms and respiratory function changes were directly related to the drug.Sphingosine-1-phosphate (S1P) is a key mediator that exerts a multitude of effects on different organs through the different S1P receptor subtypes that are expressed in a wide variety of tissues. These regulate a large range of biological functions, including lymphocyte trafficking, vascular permeability, and bronchial tone. In experimental trials in mice, S1P has been seen to intervene in multiple stages of the asthmatic response through activation of the S1PR1 and S1PR3 receptor subtypes. In this way, it promotes the contraction of smooth muscle cells in the respiratory tract and regulates the activation of mast cells and eosinophils, producing an inflammatory response and remodeling of bronchial tissue.<a class="elsevierStyleCrossRef" href="#bib0045">3</a>According to the package insert, ponesimod should be used with caution in patients with severe respiratory disease, pulmonary fibrosis and chronic obstructive pulmonary disease, because dose-dependent reductions in FEV1 and reductions in lung carbon monoxide diffusion capacity (DLCO) have been observed, mainly during the first month after starting treatment.<a class="elsevierStyleCrossRef" href="#bib0050">4</a>No cases have been published to date on symptomatic bronchoconstriction due to ponesimod in patients with multiple sclerosis in routine clinical practice, but 2 cases of worsening asthma caused by fingolimod have been reported.<a class="elsevierStyleCrossRefs" href="#bib0055">5,6</a> This is a drug with a mechanism of action similar to ponesimod that involves sphingosine-1-phosphate receptor modulation.This case report highlights the risk of bronchoconstriction associated with ponesimod, which can produce symptoms that can limit normal activity, even in patients without a history of respiratory disease. Therefore, all patients treated with ponesimod should be closely monitored for the appearance of respiratory symptoms and spirometry should be considered to determine respiratory function during treatment, not only in patients with a history of previous respiratory disease, but also in individuals who report dyspnea or other respiratory symptoms. It is important to be aware of this possible adverse effect when prescribing ponesimod to patients with multiple sclerosis.FundingThis study has not received funding of any kind.Conflict of InterestsThere are no conflicts of interest directly or indirectly related to the contents of the manuscript." "textoCompletoSecciones" => array:1 [ "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Conflict of Interests" ] 2 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "The following are the supplementary data to this article:<elsevierMultimedia ident="upi0005"></elsevierMultimedia>" "etiqueta" => "Appendix A" "titulo" => "Supplementary data" "identificador" => "sec0020" ] ] ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 501 "Ancho" => 1675 "Tamanyo" => 58199 ] ] "descripcion" => array:1 [ "en" => "Flow-volume chart (left) and volume-time chart (right). Blue line: baseline spirometry; red line: post-bronchodilator." ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 805 "Ancho" => 1258 "Tamanyo" => 51089 ] ] "descripcion" => array:1 [ "en" => "Flow-volume chart after discontinuing ponesimod." ] ] 2 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.pdf" "ficheroTamanyo" => 196976 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:6 [ 0 => array:3 [ "identificador" => "bib0035" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ponesimod: first approval" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Markham" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40265-021-01523-z" "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2021" "volumen" => "81" "paginaInicial" => "957" "paginaFinal" => "962" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33939119" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0040" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Kappos" 1 => "R.J. Fox" 2 => "M. Burcklen" 3 => "M.S. Freedman" 4 => "E.K. Havrdová" 5 => "B. Hennessy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamaneurol.2021.0405" "Revista" => array:6 [ "tituloSerie" => "JAMA Neurol" "fecha" => "2021" "volumen" => "78" "paginaInicial" => "558" "paginaFinal" => "567" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33779698" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0045" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sphingolipid metabolites in inflammatory disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Maceyka" 1 => "S. Spiegel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nature13475" "Revista" => array:6 [ "tituloSerie" => "Nature" "fecha" => "2014" "volumen" => "510" "paginaInicial" => "58" "paginaFinal" => "67" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24899305" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0050" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica de ponesimod. Available from: <a target="_blank" href="https://cima.aemps.es/cima/pdfs/ft/1211550002/FT_1211550002.pdf">https://cima.aemps.es/cima/pdfs/ft/1211550002/FT_1211550002.pdf</a> [accessed 7th April]." ] ] ] 4 => array:3 [ "identificador" => "bib0055" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.A. Van Rossum" 1 => "E.E. Looysen" 2 => "J.M. Daniels" 3 => "J. Killestein" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1352458514531844" "Revista" => array:6 [ "tituloSerie" => "Mult Scler" "fecha" => "2014" "volumen" => "20" "paginaInicial" => "1792" "paginaFinal" => "1793" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24866203" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0060" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Life-threatening asthma attack during prolonged fingolimod treatment: case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C. Zecca" 1 => "M. Caporro" 2 => "S. Györik" 3 => "C. Gobbi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/PPA.S65708" "Revista" => array:6 [ "tituloSerie" => "Patient Prefer Adherence" "fecha" => "2014" "volumen" => "8" "paginaInicial" => "987" "paginaFinal" => "989" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25053881" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03002896/0000005900000010/v2_202312180422/S0300289623001837/v2_202312180422/en/main.assets" "Apartado" => array:4 [ "identificador" => "93560" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Scientific Letters" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/03002896/0000005900000010/v2_202312180422/S0300289623001837/v2_202312180422/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623001837?idApp=UINPBA00003Z"]

Statistics

Scientific Letter

Dyspnea and Bronchoconstriction in a Young Patient With Multiple Sclerosis Treated With Ponesimod

Marta Gómez Romána,b,

Corresponding author

martagoro13@gmail.com

Corresponding author.

, Maria del Mar García Ródenasa,b, Luis Moreno Navarroc,d, Santos Asensio Sáncheza,b, Ángel Pérez Semperec,d,e

a Servicio de Neumología, Hospital General Universitario Dr. Balmis, Spain

b Instituto de Investigación Sanitaria Biomédica de Alicante (ISABIAL), Alicante, Spain

c Servicio de Neurología, Hospital General Universitario Dr. Balmis, Alicante, Spain

d Instituto de Investigación Sanitaria Biomédica de Alicante (ISABIAL), Grupo 1: Investigación en Neurociencias, Spain

e Departamento de Medicina Clínica, Universidad Miguel Hernández, Spain

Read

1647

Times
was read the article

433

Total PDF

1214

Total HTML

Share statistics

 array:23 [
  "pii" => "S0300289623001837"
  "issn" => "03002896"
  "doi" => "10.1016/j.arbres.2023.05.018"
  "estado" => "S300"
  "fechaPublicacion" => "2023-10-01"
  "aid" => "3336"
  "copyright" => "SEPAR"
  "copyrightAnyo" => "2023"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Arch Bronconeumol. 2023;59:676-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0300289623001898"
    "issn" => "03002896"
    "doi" => "10.1016/j.arbres.2023.06.008"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3342"
    "copyright" => "SEPAR"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Arch Bronconeumol. 2023;59:678-80"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>"
      "titulo" => "Do Smokers Who Only Attend the First Appointment of a Smoking Cessation Consultation Have Distinguishing Characteristics&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "678"
          "paginaFinal" => "680"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Jos&#233; Ignacio de Granda-Orive, Jos&#233; Francisco Pascual-Lled&#243;, Santos Asensio-S&#225;nchez, Segismundo Solano-Reina, Marcos Garc&#237;a-Rueda, Manuel &#193;ngel Mart&#237;nez-Mu&#241;iz, Lourdes L&#225;zaro-Asegurado, Daniel Buljubasich, Susana Luhning, Rogelio Pendino, Isabel Cienfuegos-Agust&#237;n, Carlos A&#46; Jim&#233;nez-Ruiz"
          "autores" => array:12 [
            0 => array:2 [
              "nombre" => "Jos&#233; Ignacio"
              "apellidos" => "de Granda-Orive"
            ]
            1 => array:2 [
              "nombre" => "Jos&#233; Francisco"
              "apellidos" => "Pascual-Lled&#243;"
            ]
            2 => array:2 [
              "nombre" => "Santos"
              "apellidos" => "Asensio-S&#225;nchez"
            ]
            3 => array:2 [
              "nombre" => "Segismundo"
              "apellidos" => "Solano-Reina"
            ]
            4 => array:2 [
              "nombre" => "Marcos"
              "apellidos" => "Garc&#237;a-Rueda"
            ]
            5 => array:2 [
              "nombre" => "Manuel &#193;ngel"
              "apellidos" => "Mart&#237;nez-Mu&#241;iz"
            ]
            6 => array:2 [
              "nombre" => "Lourdes"
              "apellidos" => "L&#225;zaro-Asegurado"
            ]
            7 => array:2 [
              "nombre" => "Daniel"
              "apellidos" => "Buljubasich"
            ]
            8 => array:2 [
              "nombre" => "Susana"
              "apellidos" => "Luhning"
            ]
            9 => array:2 [
              "nombre" => "Rogelio"
              "apellidos" => "Pendino"
            ]
            10 => array:2 [
              "nombre" => "Isabel"
              "apellidos" => "Cienfuegos-Agust&#237;n"
            ]
            11 => array:2 [
              "nombre" => "Carlos A&#46;"
              "apellidos" => "Jim&#233;nez-Ruiz"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623001898?idApp=UINPBA00003Z"
    "url" => "/03002896/0000005900000010/v2_202312180422/S0300289623001898/v2_202312180422/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0300289623002752"
    "issn" => "03002896"
    "doi" => "10.1016/j.arbres.2023.08.004"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3383"
    "copyright" => "SEPAR"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Arch Bronconeumol. 2023;59:675"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Clinical Image</span>"
      "titulo" => "Fanning Technique for Endobronchial Ultrasound-Guided Transbronchial Mediastinal Cryobiopsy&#58; It is Possible"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "675"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1245
              "Ancho" => 1908
              "Tamanyo" => 193385
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">EBUS image showing the 1&#46;1<span class="elsevierStyleHsp" style=""></span>mm cryo-probe inside the station 7 lymph node&#46; By performing the fanning technique&#44; we were able to accurately place the cryo-probe in multiple zones of the lymph node&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Miguel Angel Ariza-Prota, Javier P&#233;rez-Pallar&#233;s, Francisco L&#243;pez-Gonz&#225;lez"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Miguel Angel"
              "apellidos" => "Ariza-Prota"
            ]
            1 => array:2 [
              "nombre" => "Javier"
              "apellidos" => "P&#233;rez-Pallar&#233;s"
            ]
            2 => array:2 [
              "nombre" => "Francisco"
              "apellidos" => "L&#243;pez-Gonz&#225;lez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623002752?idApp=UINPBA00003Z"
    "url" => "/03002896/0000005900000010/v2_202312180422/S0300289623002752/v2_202312180422/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>"
    "titulo" => "Dyspnea and Bronchoconstriction in a Young Patient With Multiple Sclerosis Treated With Ponesimod"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">To the Director</span>&#44;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "676"
        "paginaFinal" => "677"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Marta G&#243;mez Rom&#225;n, Maria del Mar Garc&#237;a R&#243;denas, Luis Moreno Navarro, Santos Asensio S&#225;nchez, &#193;ngel P&#233;rez Sempere"
        "autores" => array:5 [
          0 => array:4 [
            "nombre" => "Marta"
            "apellidos" => "G&#243;mez Rom&#225;n"
            "email" => array:1 [
              0 => "martagoro13@gmail.com"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Maria del Mar"
            "apellidos" => "Garc&#237;a R&#243;denas"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Luis"
            "apellidos" => "Moreno Navarro"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Santos"
            "apellidos" => "Asensio S&#225;nchez"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "&#193;ngel"
            "apellidos" => "P&#233;rez Sempere"
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:5 [
          0 => array:3 [
            "entidad" => "Servicio de Neumolog&#237;a&#44; Hospital General Universitario Dr&#46; Balmis&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Instituto de Investigaci&#243;n Sanitaria Biom&#233;dica de Alicante &#40;ISABIAL&#41;&#44; Alicante&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Neurolog&#237;a&#44; Hospital General Universitario Dr&#46; Balmis&#44; Alicante&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Instituto de Investigaci&#243;n Sanitaria Biom&#233;dica de Alicante &#40;ISABIAL&#41;&#44; Grupo 1&#58; Investigaci&#243;n en Neurociencias&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Departamento de Medicina Cl&#237;nica&#44; Universidad Miguel Hern&#225;ndez&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 805
            "Ancho" => 1258
            "Tamanyo" => 51089
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Flow-volume chart after discontinuing ponesimod&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The emergence of immunotherapy for the treatment of autoimmune diseases has revolutionized the management of many diseases in recent years&#44; including multiple sclerosis &#40;MS&#41;&#46; Ponesimod is a highly selective sphingosine-1-phosphate receptor &#40;S1PR&#41; modulator that shows high-affinity binding to subtype 1 &#40;S1PR1&#41; in lymphocytes and other cells&#46; Ponesimod prevents lymphocytes from leaving the lymph nodes&#44; thus reducing their concentration in peripheral blood&#46; Its mechanism of action in MS has not been fully clarified&#44; but its therapeutic effects are probably associated with the reduced migration of lymphocytes to the central nervous system &#40;CNS&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">1&#44;2</span></a> This drug has been marketed in Spain for the treatment of recurrent forms of MS since 2022&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">We report a little-known adverse effect in a young woman with no respiratory history who&#44; after starting ponesimod&#44; developed symptoms of progressive dyspnea reaching modified scale of the Medical Research Council &#40;mMRC&#41; grade 3 and mild obstruction with bronchial reversibility in spirometry&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Our patient was a 34-year-old woman diagnosed in 2011 with relapsing-remitting MS&#46; After therapeutic failure with cladribine&#44; she began treatment with ponesimod in January 2023&#46; Neurological examination on starting ponesimod was normal&#46; Within 3 weeks of administration&#44; the patient developed dyspnea that limited her activities of daily living&#44; eventually reaching mMRC grade 3&#46; In view of these symptoms&#44; she was referred to the respiratory medicine department for further investigation&#46; The patient reported no cough&#44; expectoration&#44; wheezing&#44; chest tightness or other symptoms associated with her dyspnea&#46; She had no history of asthma or bronchial hyperreactivity during respiratory infections&#46; She had no known respiratory history&#44; no history of nasal polyposis&#44; no NSAID intolerance&#44; no IgE elevation or peripheral eosinophilia&#44; and had never required bronchodilator treatment&#46; Spirometry was performed&#44; showing FVC 4550<span class="elsevierStyleHsp" style=""></span>ml &#40;107&#37;&#41;&#44; FEV1 3040<span class="elsevierStyleHsp" style=""></span>ml &#40;86&#37;&#41;&#44; FEV1&#47;FVC 0&#46;67 &#40;80&#37; predicted&#41;&#44; consistent with mild obstructive ventilatory airflow changes&#46; A bronchodilator challenge with 400<span class="elsevierStyleHsp" style=""></span>mcg of salbutamol produced a significant 16&#46;7&#37; improvement in FEV1 from baseline &#40;510<span class="elsevierStyleHsp" style=""></span>ml&#41;&#44; 14&#46;5&#37; improvement in predicted value&#44; and reversibility of obstruction with normalization of FEV1&#47;FVC &#40;0&#46;75&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; A pulmonary carbon monoxide diffusion &#40;DLCO&#41; test was performed with a result of 107&#37; &#40;within normal limits&#41; and an exhaled nitric oxide &#40;FeNO&#41; measurement of 23<span class="elsevierStyleHsp" style=""></span>ppb&#46; The study was completed with high-resolution computed tomography of the chest that revealed no significant radiological alterations&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">Given these findings&#44; we initially planned to start bronchodilator treatment&#44; but the temporal relationship of symptoms with the start of ponesimod suggested that bronchoconstriction was due to this therapy&#44; so we decided to discontinue the drug and replace it with ofatumumab&#44; an anti-CD20 monoclonal antibody&#44; without adding bronchodilator therapy&#46; The patient&#39;s respiratory symptoms resolved 2 weeks after discontinuing ponesimod&#46; Spirometry was repeated showing parameters within normal limits&#58; FEV1 5060<span class="elsevierStyleHsp" style=""></span>ml &#40;118&#37;&#41;&#44; FEV1 3760<span class="elsevierStyleHsp" style=""></span>ml &#40;106&#37;&#41;&#44; FEV1&#47;FVC 74&#37; &#40;89&#37; predicted&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">The patient&#39;s good progress following discontinuation of ponesimod&#44; with resolution of dyspnea and normalization of spirometry values&#44; suggests that her symptoms and respiratory function changes were directly related to the drug&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Sphingosine-1-phosphate &#40;S1P&#41; is a key mediator that exerts a multitude of effects on different organs through the different S1P receptor subtypes that are expressed in a wide variety of tissues&#46; These regulate a large range of biological functions&#44; including lymphocyte trafficking&#44; vascular permeability&#44; and bronchial tone&#46; In experimental trials in mice&#44; S1P has been seen to intervene in multiple stages of the asthmatic response through activation of the S1PR1 and S1PR3 receptor subtypes&#46; In this way&#44; it promotes the contraction of smooth muscle cells in the respiratory tract and regulates the activation of mast cells and eosinophils&#44; producing an inflammatory response and remodeling of bronchial tissue&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">3</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">According to the package insert&#44; ponesimod should be used with caution in patients with severe respiratory disease&#44; pulmonary fibrosis and chronic obstructive pulmonary disease&#44; because dose-dependent reductions in FEV1 and reductions in lung carbon monoxide diffusion capacity &#40;DLCO&#41; have been observed&#44; mainly during the first month after starting treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">4</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">No cases have been published to date on symptomatic bronchoconstriction due to ponesimod in patients with multiple sclerosis in routine clinical practice&#44; but 2 cases of worsening asthma caused by fingolimod have been reported&#46;<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">5&#44;6</span></a> This is a drug with a mechanism of action similar to ponesimod that involves sphingosine-1-phosphate receptor modulation&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">This case report highlights the risk of bronchoconstriction associated with ponesimod&#44; which can produce symptoms that can limit normal activity&#44; even in patients without a history of respiratory disease&#46; Therefore&#44; all patients treated with ponesimod should be closely monitored for the appearance of respiratory symptoms and spirometry should be considered to determine respiratory function during treatment&#44; not only in patients with a history of previous respiratory disease&#44; but also in individuals who report dyspnea or other respiratory symptoms&#46; It is important to be aware of this possible adverse effect when prescribing ponesimod to patients with multiple sclerosis&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding</span><p id="par0050" class="elsevierStylePara elsevierViewall">This study has not received funding of any kind&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Conflict of Interests</span><p id="par0055" class="elsevierStylePara elsevierViewall">There are no conflicts of interest directly or indirectly related to the contents of the manuscript&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:3 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Funding"
        ]
        1 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Conflict of Interests"
        ]
        2 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0065" class="elsevierStylePara elsevierViewall">The following are the supplementary data to this article&#58;<elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>"
            "etiqueta" => "Appendix A"
            "titulo" => "Supplementary data"
            "identificador" => "sec0020"
          ]
        ]
      ]
    ]
    "multimedia" => array:3 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 501
            "Ancho" => 1675
            "Tamanyo" => 58199
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Flow-volume chart &#40;left&#41; and volume-time chart &#40;right&#41;&#46; Blue line&#58; baseline spirometry&#59; red line&#58; post-bronchodilator&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Fig&#46; 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 805
            "Ancho" => 1258
            "Tamanyo" => 51089
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Flow-volume chart after discontinuing ponesimod&#46;</p>"
        ]
      ]
      2 => array:5 [
        "identificador" => "upi0005"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "Ecomponente" => array:2 [
          "fichero" => "mmc1.pdf"
          "ficheroTamanyo" => 196976
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:6 [
            0 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ponesimod&#58; first approval"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "A&#46; Markham"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40265-021-01523-z"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drugs"
                        "fecha" => "2021"
                        "volumen" => "81"
                        "paginaInicial" => "957"
                        "paginaFinal" => "962"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33939119"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study&#58; a randomized clinical trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Kappos"
                            1 => "R&#46;J&#46; Fox"
                            2 => "M&#46; Burcklen"
                            3 => "M&#46;S&#46; Freedman"
                            4 => "E&#46;K&#46; Havrdov&#225;"
                            5 => "B&#46; Hennessy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamaneurol.2021.0405"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Neurol"
                        "fecha" => "2021"
                        "volumen" => "78"
                        "paginaInicial" => "558"
                        "paginaFinal" => "567"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33779698"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sphingolipid metabolites in inflammatory disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46; Maceyka"
                            1 => "S&#46; Spiegel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/nature13475"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nature"
                        "fecha" => "2014"
                        "volumen" => "510"
                        "paginaInicial" => "58"
                        "paginaFinal" => "67"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24899305"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios&#46; Ficha t&#233;cnica de ponesimod&#46; Available from&#58; <a target="_blank" href="https://cima.aemps.es/cima/pdfs/ft/1211550002/FT_1211550002.pdf">https&#58;&#47;&#47;cima&#46;aemps&#46;es&#47;cima&#47;pdfs&#47;ft&#47;1211550002&#47;FT&#95;1211550002&#46;pdf</a> &#91;accessed 7th April&#93;&#46;"
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46;A&#46; Van Rossum"
                            1 => "E&#46;E&#46; Looysen"
                            2 => "J&#46;M&#46; Daniels"
                            3 => "J&#46; Killestein"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1352458514531844"
                      "Revista" => array:6 [
                        "tituloSerie" => "Mult Scler"
                        "fecha" => "2014"
                        "volumen" => "20"
                        "paginaInicial" => "1792"
                        "paginaFinal" => "1793"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24866203"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Life-threatening asthma attack during prolonged fingolimod treatment&#58; case report"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "C&#46; Zecca"
                            1 => "M&#46; Caporro"
                            2 => "S&#46; Gy&#246;rik"
                            3 => "C&#46; Gobbi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/PPA.S65708"
                      "Revista" => array:6 [
                        "tituloSerie" => "Patient Prefer Adherence"
                        "fecha" => "2014"
                        "volumen" => "8"
                        "paginaInicial" => "987"
                        "paginaFinal" => "989"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25053881"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/03002896/0000005900000010/v2_202312180422/S0300289623001837/v2_202312180422/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "93560"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Scientific Letters"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/03002896/0000005900000010/v2_202312180422/S0300289623001837/v2_202312180422/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623001837?idApp=UINPBA00003Z"
]

Article information

ISSN: 03002896
Original language: English

DOI:10.1016/j.arbres.2023.05.018

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	5	1	6
2024 October	57	14	71
2024 September	57	10	67
2024 August	83	37	120
2024 July	55	11	66
2024 June	60	16	76
2024 May	56	18	74
2024 April	69	17	86
2024 March	53	17	70
2024 February	77	25	102
2024 January	69	28	97
2023 December	84	21	105
2023 November	89	34	123
2023 October	199	49	248
2023 September	34	30	64
2023 August	23	24	47
2023 July	65	49	114
2023 June	79	32	111

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter